Literature DB >> 3498449

The effect of cardiopulmonary bypass on T cells and their subpopulations.

H Ide, T Kakiuchi, N Furuta, H Matsumoto, K Sudo, A Furuse, K Asano.   

Abstract

To investigate the effect of cardiopulmonary bypass (CPB) on T cells, lymphocyte subsets of peripheral blood and lymphoid organs were monitored during and after open-heart surgery (Group 1). As a control, lymphocyte subsets of peripheral blood were measured in patients undergoing thoracovascular operations without CPB (Group 2). In Group 1, analysis of each subset-to-total lymphocyte ratio revealed that observed lymphocytopenia in the early postoperative days was mainly the result of T cell reduction, and that the decrease of helper/inducer T cells contributed to this decrease. In contrast, no significant fluctuation of any lymphocyte subpopulation ratio was observed in Group 2. Analysis of lymphocyte subpopulation ratios in lymphoid organs showed that reciprocal changes of T cells and their subsets were observed in the bone marrow, thus indicating that the redistribution of T cells (especially of helper/inducer cells) seems to occur between peripheral blood and bone marrow in Group 1. Furthermore, there was no relationship between serum cortisol levels and the changes in lymphocyte subset ratios in Group 1 patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498449     DOI: 10.1016/s0003-4975(10)62074-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

1.  Adaptive immunity is severely impaired by open-heart surgery.

Authors:  Tetsuro Sano; Shigeki Morita; Ryuji Tominaga; Munetaka Masuda; Yukihiro Tomita; Toru Yasutsune; Hisataka Yasui
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-05

2.  Perioperative measurements of IL-6 and α-melanocyte stimulating hormone in a cardiac transplant patient after ventricular assist device support.

Authors:  T Sakai; A Kudoh; N Kotani; T W Latson; A H Giesecke; A Matsuki
Journal:  J Anesth       Date:  1995-03       Impact factor: 2.078

3.  Perioperative serum levels of tumour-necrosis-factor alpha (TNF-alpha), IL-1 beta, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution.

Authors:  A Roth-Isigkeit; T V Borstel; M Seyfarth; P Schmucker
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

4.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

5.  Effect of cardiopulmonary bypass on the specific immunity of the host.

Authors:  Q Lü; H J Lan; J J Cai; Z Q Sun
Journal:  J Tongji Med Univ       Date:  1993

6.  Serum levels of IL-1, IL-6 and tumour necrosis factors in patients undergoing coronary artery bypass grafts or cholecystectomy.

Authors:  N Lahat; A Y Zlotnick; R Shtiller; I Bar; G Merin
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

7.  Responses of interleukin-6 and tumor necrosis factor during and after cardiac surgery undergoing cardiopulmonary bypass and pancreatoduodenectomy.

Authors:  Mitsuhiro Nishimura; Kazuo Abe; Tetsuo Sakakibara; Kazuyasu Nakao; Ikuto Yoshiya
Journal:  J Anesth       Date:  1995-06       Impact factor: 2.078

8.  Successful aortic valve replacement in a patient with AIDS.

Authors:  L Penninga; J R Lahpor; L R van der Wieken
Journal:  Neth Heart J       Date:  2002-06       Impact factor: 2.380

9.  Hypertonic saline attenuates the hormonal response to injury.

Authors:  J S Cross; D P Gruber; D S Gann; A K Singh; J M Moran; K W Burchard
Journal:  Ann Surg       Date:  1989-06       Impact factor: 12.969

10.  Plasma levels of immunosuppressive mediators during cardiopulmonary bypass.

Authors:  E Borrelli; P Giomarelli; A Naldini; E Luzzi; S Silvestri; M Gardinali; V Bocci
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.